Year-End Submission Rate Stabilizes In 2005 As NDA Approvals Drop
This article was originally published in Pharmaceutical Approvals Monthly
The slow-down in year-end FDA submissions in recent years appears to have stabilized in 2005, with 16 filings in December – up slightly from 13 in December 2004.
You may also be interested in...
Replidyne is conducting an additional Phase III trial of its oral beta-lactam antibiotic Orapem in anticipation of an FDA request for additional studies, according to the firm’s initial public offering prospectus.
Allergan and partner Sirna hope to advance novel RNAi-based retinal disease agent Sirna-027 into Phase II trials for macular degeneration this year, according to Allergan